N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation

DISEASE CHARACTERISTICS: * Diagnosis of neuroblastoma * Confirmed by at least 1 of the following methods: * Histology * Clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites * High-risk disease * Poor response to induction therapy OR relapse defined by any of the following: * No response, stable disease, or mixed response after a minimum of 3 prior courses of chemotherapy * More than 100 tumor cells per 10\^5 nucleated cells on bone marrow immunocytology after at least 3 prior courses of chemotherapy * Progressive disease at any time during or after therapy * Patients with massive bone marrow invasion (more than 50% replacement of bone marrow by tumor cells) are allowed * Must have positive iodine I 131 metaiodobenzylguanidine (\^131I-MIBG) within the past 6 weeks or subsequent to any other prior antitumor therapy delivered within the past 6 weeks * Must meet the following criteria for minimum number of autologous stem cells: * Unpurged peripheral blood stem cells (PBSC) * Minimum of 1,500,000/mm\^3 CD34-positive cells/kg * Collected products must have \< 1 tumor cell/100,000 normal cells by immunocytology * PBSC purged with immunomagnetic beads * Minimum of 1,000,000/mm\^3 viable CD34-positive cells/kg * Collected products must have \< 1 tumor cell/100,000 normal cells by immunocytology * CD34-positive selected PBSC products are not allowed * Patients who had PBSC collected…